CD8A and neoplasm: This involves inhibition of anti-tumor effector immune cells, such as NK cells and CD8+ T cells and recruitment and differentiation of immune-suppressive and/or anti-inflammatory cells, such as regulatory T cells (Tregs), dendritic cells (DCs), Th17 cells, M2-polarized tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) (230).